GW6471
Based on 82 publication(s) in Google Scholar
GW6471 is a selective peroxisome proliferator-activated receptor α (PPARα) antagonist. GW6471 reduces cancer stem cell viability, proliferation, and spheroid formation. GW6471 induces apoptosis and causes metabolic impairment including energy imbalance. GW6471 can be used for the research of paragangliomas and triple-negative breast cancer.
For research use only. We do not sell to patients.
- Purity: 99.64%
- CAS No.: 880635-03-0
- Formula: C35H36F3N3O4
- Molecular Weight:619.67
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Anti-Obesity Compound Library
HY-L087
-
Transcription Factor-Targeted Library
HY-L090
-
Lipid Metabolism Compound Library
HY-L091
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
Nuclear Receptor Compound Library
HY-L126
-
Metabolic Enzyme Compound Library
HY-L146
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Brain Cancer Compound Library
HY-L188
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) GW6471
More- Cell Metab. 2025 Aug 29:S1550-4131(25)00361-4. [Abstract]
- Immunity. 2024 Jun 19:S1074-7613(24)00305-4. [Abstract]
- Gut. 2021 Nov;70(11):2183-2195. [Abstract]
- Nat Metab. 2026 Jan;8(1):74-95. [Abstract]
- Cell Stem Cell. 2022 Sep 1;29(9):1366-1381.e9. [Abstract]
- Cell Mol Immunol. 2026 May;23(5):491-504.
- Cell Host Microbe. 2026 Jun 3:S1931-3128(26)00181-2.
- ACS Nano. 2026 May 5;20(17):12859-12877.
- Exp Mol Med. 2026 May;58(5):1642-1656.
- Exp Mol Med. 2025 Mar;57(3):652-666. [Abstract]
- J Exp Clin Cancer Res. 2025 Nov 24;45(1):1.
- Environ Sci Technol. 2025 Mar 4;59(8):3853-3868. [Abstract]
- Pharmacol Res. 2021 Jul:169:105640. [Abstract]
- Environ Int. 2023 Aug:178:108138. [Abstract]
- Cell Death Dis. 2025 May 9;16(1):371. [Abstract]
- Cell Death Dis. 2022 Nov 23;13(11):987. [Abstract]
- Genes Dis. 2020 Nov 21;8(6):867-881. [Abstract]
- Cell Commun Signal. 2024 Oct 25;22(1):519. [Abstract]
- Int J Biol Macromol. 2023 Jun 1:239:124293. [Abstract]
- Acta Pharmacol Sin. 2025 Jun 11. [Abstract]
- Phytomedicine. 2026 Aug:158:158332.
- Phytomedicine. 2023 Feb 24;113:154726. [Abstract]
- Food Res Int. 2026 Jul 31:236:119215.
- Environ Pollut. 2024 Feb 15:343:123167. [Abstract]
- Environ Pollut. 2021 Nov 1:288:117792. [Abstract]
- Cell Rep. 2023 Nov 13;42(11):113424. [Abstract]
- Cell Rep. 2023 Oct 3;42(10):113211. [Abstract]
- Antioxidants (Basel). 2024 Nov 24;13(12):1446. [Abstract]
- Mol Med. 2024 Dec 20;30(1):254. [Abstract]
- J Environ Sci. 2025 Sep 20.
- J Agric Food Chem. 2024 Nov 6;72(44):24417-24431. [Abstract]
- Food Biosci. 2024 Dec.
- Int J Mol Med. 2026 Apr;57(4):102. [Abstract]
- Chin Med. 2025 Jan 24;20(1):13. [Abstract]
- World J Gastroenterol. 2026 Mar 7;32(9):114544. [Abstract]
- J Ethnopharmacol. 2025 Sep 6;355(Pt A):120571. [Abstract]
- Food Funct. 2024 May 20;15(10):5485-5495. [Abstract]
- J Ethnopharmacol. 2024 Mar 1:321:117532. [Abstract]
- Mar Drugs. 2020 Apr 21;18(4):222. [Abstract]
- Chin J Nat Med. 2021 Jun;19(6):401-411. [Abstract]
- Biomolecules. 2025 Mar 27;15(4):492. [Abstract]
- Eur J Pharmacol. 2026 Jul 10:1029:178995. [Abstract]
- Int Immunopharmacol. 2026 May 14:182:116849.
- Eur J Pharmacol. 2026 Jul 10:1029:179008. [Abstract]
- Int Immunopharmacol. 2025 Apr 16:152:114470. [Abstract]
- Eur J Pharmacol. 2023 Oct 15:957:175982. [Abstract]
- Eur J Pharmacol. 2023 Sep 5:954:175864. [Abstract]
- Int Immunopharmacol. 2022 Oct:111:109058. [Abstract]
- Cancers (Basel). 2024 Aug 30;16(17):3028. [Abstract]
- J Dairy Sci. 2023 Apr;106(4):2271-2288. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2025 May 24:167919. [Abstract]
- Animal. 2025 Apr 3;19(5):101505. [Abstract]
- FASEB J. 2023 Aug;37(8):e23070. [Abstract]
- Mol Nutr Food Res. 2023 Aug;67(16):e2200499. [Abstract]
- J Cell Mol Med. 2020 Mar;24(6):3384-3398. [Abstract]
- Toxics. 2024 Mar 14;12(3):214. [Abstract]
- J Inflamm Res. 2022 Aug 22;15:4763-4784. [Abstract]
- J Cell Physiol. 2021 Mar;236(3):1889-1902. [Abstract]
- Sci Rep. 2024 Jul 2;14(1):15246. [Abstract]
- Fish Shellfish Immunol. 2021 Dec:119:114-127. [Abstract]
- Heliyon. 2023 Aug 19;9(8):e19150. [Abstract]
- BMC Cancer. 2019 Dec 2;19(1):1166. [Abstract]
- PPAR Res. 2020 Dec 14:2020:6661642. [Abstract]
- Immunol Res. 2020 Feb;68(1):28-38. [Abstract]
- J Biochem Mol Toxicol. 2024 Aug;38(8):e23802. [Abstract]
- Hereditas. 2025 Oct 1;162(1):201. [Abstract]
- Theriogenology. 2025 Nov:247:117570. [Abstract]
- Toxicon. 2025 Apr 23:261:108371. [Abstract]
- Behav Brain Res. 2026 Jun 25:508:116215. [Abstract]
- BMC Neurosci. 2023 Jul 20;24(1):37. [Abstract]
- Urolithiasis. 2025 Nov 18;53(1):222. [Abstract]
- Islets. 2026 Dec 31;18(1):2633793. [Abstract]
- Res Sq. 2026 Jun 5.
- bioRxiv. 2026 May 27.
- SSRN. 2025 May 10.
- bioRxiv. 2025 January 22.
- Res Sq. 2024 Oct 29.
- Research Square Preprint. 2023 Oct 16.
- Oxid Med Cell Longev. 2022 Jun 20;2022:5905374. [Abstract]
- Evid Based Complement Alternat Med. 2022 Jan 7:2022:1124901. [Abstract]
- Oxid Med Cell Longev. 2021 Feb 25:2021:2045259. [Abstract]
- Oxid Med Cell Longev. 2019 Nov 3;2019:7536803. [Abstract]
Customer Validation & Images
-
WB
-
IF
-
RT-PCR
Biological Activity
|
PPARα |
GW6471 (7-16 μM; 72 h) reduces cell viability in PTJ64i and PTJ86i head and neck paraganglioma cell lines at 16 μM[1].
GW6471 (7-16 μM; 72 h) impairs clonogenicity in PTJ64i and PTJ86i head and neck paraganglioma cell lines, with 16 μM causing a more drastic reduction in colony-forming capacity than 7 μM[1].
GW6471 (4-16 μM; 72 h) dose-dependently reduces cell viability in MDA-MB-231-derived breast cancer stem cell mammospheres, with significant effects observed at 4 μM, 8 μM, and 16 μM after 72 hours of treatment[3].
GW6471 (8 μM; 72 h) induces significant cytotoxicity in MDA-MB-231-derived breast cancer stem cell mammospheres[3].
GW6471 (8 μM; 72 h) significantly inhibits spheroid growth in MDA-MB-231-derived breast cancer stem cell mammospheres[3].
GW6471 (8 μM; 72 h) induces G1 phase cell cycle arrest and intrinsic pathway apoptosis in MDA-MB-231-derived breast cancer stem cell mammospheres[3].
GW6471 (8 μM; 72 h) activates caspase 3/7, confirming apoptotic induction in MDA-MB-231-derived breast cancer stem cell mammospheres[3].
GW6471 (8 μM; 72 h) activates p-AMPK, reduces lipid droplet and cholesterol levels, and downregulates mevalonate pathway gene expression in MDA-MB-231-derived breast cancer stem cell mammospheres[3].
GW6471 (8 μM; 72 h) impairs glucose metabolism in MDA-MB-231-derived breast cancer stem cell mammospheres by downregulating key glycolytic proteins, reducing glucose uptake, and decreasing lactate production[3].
GW6471 (8 μM; 72 h) upregulates CD36 and induces nuclear translocation of PPARγ in MDA-MB-231-derived breast cancer stem cell mammospheres[3].
GW6471 (8 μM; 72 h) activates GSK3β and reduces cytoplasmic/nuclear β-catenin while increasing membrane-associated β-catenin in MDA-MB-231-derived breast cancer stem cell mammospheres[3].
GW6471 (8 μM; 72 h) reduces YAP/TAZ activity, downregulates Rho family proteins, and inhibits invasion in MDA-MB-231-derived breast cancer stem cell mammospheres[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:PTJ64i, PTJ86i (head and neck paraganglioma cell lines)
-
Concentration:7 μM; 16 μM
-
Incubation Time:72 h
-
Result:Reduced cell viability in PTJ64i and PTJ86i head and neck paraganglioma cell lines at 16 μM.
Impaired clonogenicity in PTJ64i and PTJ86i head and neck paraganglioma cell lines, with 16 μM causing a more drastic reduction in colony-forming capacity than 7 μM
-
Cell Line:MDA-MB-231-derived breast cancer stem cell mammospheres
-
Concentration:4 μM; 8 μM; 16 μM
-
Incubation Time:72 h
-
Result:Reduced cell viability to ~70% of control at 4 μM.
Reduced cell viability to ~40% of control at 8 μM.
Reduced cell viability to ~25% of control at 16 μM.
-
Cell Line:MDA-MB-231-derived breast cancer stem cell mammospheres
-
Concentration:8 μM
-
Incubation Time:72 h
-
Result:Increased mean fluorescence intensity (cytotoxicity) in a time-dependent manner over 72 hours.
Showed significantly higher cytotoxicity levels compared to untreated controls at all time points after 0 hours.
-
Cell Line:MDA-MB-231-derived breast cancer stem cell mammospheres
-
Concentration:8 μM
-
Incubation Time:72 h
-
Result:Induced G1 phase cell cycle arrest and intrinsic pathway apoptosis.
-
Cell Line:MDA-MB-231-derived breast cancer stem cell mammospheres
-
Concentration:8 μM
-
Incubation Time:72 h
-
Result:Increased mean fluorescence intensity indicating caspase 3/7 activation over the 72-hour period.
Chemical Information
-
CAS No. 880635-03-0
-
Appearance Solid
-
Molecular Weight 619.67
-
Formula C35H36F3N3O4
-
Color Off-white to yellow
-
SMILES
CCC(NC[C@@H](N/C(C)=C\C(C1=CC=C(C(F)(F)F)C=C1)=O)CC2=CC=C(OCCC3=C(C)OC(C4=CC=CC=C4)=N3)C=C2)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (82)
-
Journal Impact Factor
-
Most Recent
-
Cell Metab
Portal vein-enriched metabolites as intermediate regulators of the gut microbiome in insulin resistance. [Abstract]2025 Aug 29:S1550-4131(25)00361-4. PMID: 40914155 -
Immunity
A metabolic switch orchestrated by IL-18 and the cyclic dinucleotide cGAMP programs intestinal tolerance. [Abstract]2024 Jun 19:S1074-7613(24)00305-4. PMID: 38906145 -
Gut
Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance. [Abstract]2021 Nov;70(11):2183-2195. PMID: 33257471 -
Nat Metab
2026 Jan;8(1):74-95. PMID: 41507665 -
Cell Stem Cell
Hepatic cytochrome P450 8B1 and cholic acid potentiate intestinal epithelial injury in colitis by suppressing intestinal stem cell renewal. [Abstract]2022 Sep 1;29(9):1366-1381.e9. PMID: 36055192 -
-
-
-
-
Exp Mol Med
LncRNA Gm35585 transcriptionally activates the peroxidase EHHADH against diet-induced fatty liver. [Abstract]2025 Mar;57(3):652-666. PMID: 40082671 -
-
Environ Sci Technol
Environmental Chemical-Induced Cardiometabolic Disorders: Combined Epidemiological and Experimental Evidence. [Abstract]2025 Mar 4;59(8):3853-3868. PMID: 39977603 -
Pharmacol Res
Medioresinol as a novel PGC-1α activator prevents pyroptosis of endothelial cells in ischemic stroke through PPARα-GOT1 axis. [Abstract]2021 Jul:169:105640. PMID: 33915296 -
Environ Int
PPARα/ACOX1 as a novel target for hepatic lipid metabolism disorders induced by per- and polyfluoroalkyl substances: An integrated approach. [Abstract]2023 Aug:178:108138. PMID: 37572494 -
Cell Death Dis
CILP1 interacting with YBX1 promotes hypertrophic scar formation by suppressing PPARs transcription. [Abstract]2025 May 9;16(1):371. PMID: 40346063 -
Cell Death Dis
LINC00924-induced fatty acid metabolic reprogramming facilitates gastric cancer peritoneal metastasis via hnRNPC-regulated alternative splicing of Mnk2. [Abstract]2022 Nov 23;13(11):987. PMID: 36418856 -
Genes Dis
2020 Nov 21;8(6):867-881. PMID: 34522714 -
Cell Commun Signal
DOT1L protects against podocyte injury in diabetic kidney disease through phospholipase C-like 1. [Abstract]2024 Oct 25;22(1):519. PMID: 39456056 -
Int J Biol Macromol
CM3-SII polysaccharide obtained from Cordyceps militaris ameliorates hyperlipidemia in heterozygous LDLR-deficient hamsters by modulating gut microbiota and NPC1L1 and PPARα levels. [Abstract]2023 Jun 1:239:124293. PMID: 37011745 -
Acta Pharmacol Sin
Targeting PPARα activation sensitizes glioblastoma cells to temozolomide and reverses acquired resistance by inhibiting H3K18 lactylation. [Abstract]2025 Jun 11. PMID: 40500345 -
-
Phytomedicine
Pectolinarigenin ameliorates acetaminophen-induced acute liver injury via attenuating oxidative stress and inflammatory response in Nrf2 and PPARa dependent manners. [Abstract]2023 Feb 24;113:154726. PMID: 36863308 -
-
Environ Pollut
Perturbation of IP3R-dependent endoplasmic reticulum calcium homeostasis by PPARδ-activated metabolic stress leads to mouse spermatocyte apoptosis: A direct mechanism for perfluorooctane sulfonic acid-induced spermatogenic disorders. [Abstract]2024 Feb 15:343:123167. PMID: 38110051 -
Environ Pollut
Mitochondria damage in ambient particulate matter induced cardiotoxicity: Roles of PPAR alpha/PGC-1 alpha signaling. [Abstract]2021 Nov 1:288:117792. PMID: 34280742 -
Cell Rep
Prostate cancer cell-derived exosomal IL-8 fosters immune evasion by disturbing glucolipid metabolism of CD8+ T cell. [Abstract]2023 Nov 13;42(11):113424. PMID: 37963015 -
Cell Rep
Lipid accumulation-mediated histone hypoacetylation drives persistent NK cell dysfunction in anti-tumor immunity. [Abstract]2023 Oct 3;42(10):113211. PMID: 37792534 -
Antioxidants (Basel)
Ginsenoside Rg1 Alleviates Blood-Milk Barrier Disruption in Subclinical Bovine Mastitis by Regulating Oxidative Stress-Induced Excessive Autophagy. [Abstract]2024 Nov 24;13(12):1446. PMID: 39765775 -
Mol Med
Deletion of lymphotoxin-β receptor (LTβR) protects against acute kidney injury by PPARα pathway. [Abstract]2024 Dec 20;30(1):254. PMID: 39707217 -
-
J Agric Food Chem
Nuciferine Alleviates High-Fat Diet- and ApoE-/--Induced Hepatic Steatosis and Ferroptosis in NAFLD Mice via the PPARα Signaling Pathway. [Abstract]2024 Nov 6;72(44):24417-24431. PMID: 39445611 -
-
Int J Mol Med
Peroxisome proliferator‑activated receptor α regulates acesulfame‑K‑induced NAFLD via hepatic PLCβ: Foe and friend. [Abstract]2026 Apr;57(4):102. PMID: 41789618 -
Chin Med
Cinnamic acid alleviates endothelial dysfunction and oxidative stress by targeting PPARδ in obesity and diabetes. [Abstract]2025 Jan 24;20(1):13. PMID: 39856769 -
World J Gastroenterol
Lianhe Xiaozhi ointment ameliorates metabolic dysfunction-associated steatotic liver disease via peroxisome proliferator-activated receptor alpha pathway activation. [Abstract]2026 Mar 7;32(9):114544. PMID: 41810443 -
J Ethnopharmacol
Chrysanthemum morifolium Ramat. water extract prevents and treats metabolic-associated fatty liver disease via pan-PPAR activity. [Abstract]2025 Sep 6;355(Pt A):120571. PMID: 40921229 -
Food Funct
Ginsenoside Rk1 improves endothelial function in diabetes through activating peroxisome proliferator-activated receptors. [Abstract]2024 May 20;15(10):5485-5495. PMID: 38690748 -
J Ethnopharmacol
The anti-hyperlipidemic effects of Poria cocos (Schw.) Wolf extract: Modulating cholesterol homeostasis in hepatocytes via PPARα pathway. [Abstract]2024 Mar 1:321:117532. PMID: 38048892 -
Mar Drugs
Anti-Inflammatory Effects of Fucoxanthinol in LPS-Induced RAW264.7 Cells through the NAAA-PEA Pathway. [Abstract]2020 Apr 21;18(4):222. PMID: 32326173 -
Chin J Nat Med
Silybin alleviates hepatic lipid accumulation in methionine-choline deficient diet-induced nonalcoholic fatty liver disease in mice via peroxisome proliferator-activated receptor α. [Abstract]2021 Jun;19(6):401-411. PMID: 34092291 -
Biomolecules
PPARs Activity Affects the Hatchability Through Lipid Metabolism Regulation in Silkworm, Bombyx mori L. [Abstract]2025 Mar 27;15(4):492. PMID: 40305260 -
Eur J Pharmacol
Isoastragaloside II modulates PPAR-α/FXR signaling and bile acid metabolism to ameliorate cholestatic liver diseases (CLD). [Abstract]2026 Jul 10:1029:178995. PMID: 42167668 -
-
Eur J Pharmacol
DTMB attenuates hepatic inflammation and lipid dysregulation via PPAR-γ modulation in diet-induced steatohepatitis. [Abstract]2026 Jul 10:1029:179008. PMID: 42173393 -
Int Immunopharmacol
The active ingredient β-sitosterol in the anti-inflammatory agents alleviates perianal inflammation in rats by inhibiting the expression of Srebf2, activating the PPAR signaling pathway, and altering the composition of gut microbiota. [Abstract]2025 Apr 16:152:114470. PMID: 40086059 -
Eur J Pharmacol
URB597 exerts neuroprotective effects against transient brain ischemia injury in mice by regulating autophagic flux and necroptosis. [Abstract]2023 Oct 15:957:175982. PMID: 37572942 -
Eur J Pharmacol
Down-regulation of Hrd1 protects against myocardial ischemia-reperfusion injury by regulating PPARα to prevent oxidative stress, endoplasmic reticulum stress, and cellular apoptosis. [Abstract]2023 Sep 5:954:175864. PMID: 37392829 -
Int Immunopharmacol
Honokiol alleviates ulcerative colitis by targeting PPAR-γ-TLR4-NF-κB signaling and suppressing gasdermin-D-mediated pyroptosis in vivo and in vitro. [Abstract]2022 Oct:111:109058. PMID: 35901530 -
Cancers (Basel)
ASCT2 Regulates Fatty Acid Metabolism to Trigger Glutamine Addiction in Basal-like Breast Cancer. [Abstract]2024 Aug 30;16(17):3028. PMID: 39272886 -
J Dairy Sci
Tandem mass tag-based quantitative proteomics analysis reveals the effects of the α-lactalbumin peptides GINY and DQW on lipid deposition and oxidative stress in HepG2 cells. [Abstract]2023 Apr;106(4):2271-2288. PMID: 36797178
GW6471 purchased from MedChemExpress. Usage Cited in: J Dairy Sci. 2023 Apr;106(4):2271-2288. [Abstract]
GW6471 significantly reduces the regulatory effects of GINY and DQW on the protein expression levels of PPARα, CPT-1a, ACOX1, HO-1, and FASN in HepG2 cells.
-
Biochim Biophys Acta Mol Basis Dis
ILF3 mediates lipid metabolism to promote pancreatic cancer development by regulating CPT1A-activated PPARa signaling pathway. [Abstract]2025 May 24:167919. PMID: 40419169 -
Animal
Oleic acid promotes lipid accumulation in bovine adipocytes: the role of peroxisome proliferator-activated receptor alpha (PPARα) signaling. [Abstract]2025 Apr 3;19(5):101505. PMID: 40300479 -
FASEB J
Hepatic Krüppel-like factor 14 regulates lipid metabolism in nonalcoholic steatohepatitis mice. [Abstract]2023 Aug;37(8):e23070. PMID: 37389939 -
Mol Nutr Food Res
α-Lactalbumin Peptide Asp-Gln-Trp Ameliorates Hepatic Steatosis and Oxidative Stress in Free Fatty Acids-Treated HepG2 Cells and High-Fat Diet-Induced NAFLD Mice by Activating the PPARα Pathway. [Abstract]2023 Aug;67(16):e2200499. PMID: 37354055 -
J Cell Mol Med
The marine-derived furanone reduces intracellular lipid accumulation in vitro by targeting LXRα and PPARα. [Abstract]2020 Mar;24(6):3384-3398. PMID: 31981312 -
Toxics
Differential Disruption of Glucose and Lipid Metabolism Induced by Phthalates in Human Hepatocytes and White Adipocytes. [Abstract]2024 Mar 14;12(3):214. PMID: 38535947 -
J Inflamm Res
The Key Molecular Mechanisms of Sini Decoction Plus Ginseng Soup to Rescue Acute Liver Failure: Regulating PPARα to Reduce Hepatocyte Necroptosis?. [Abstract]2022 Aug 22;15:4763-4784. PMID: 36032938 -
J Cell Physiol
Icariin ameliorates endothelial dysfunction in type 1 diabetic rats by suppressing ER stress via the PPARα/Sirt1/AMPKα pathway. [Abstract]2021 Mar;236(3):1889-1902. PMID: 32770555 -
Sci Rep
Activation of PPAR-α attenuates myocardial ischemia/reperfusion injury by inhibiting ferroptosis and mitochondrial injury via upregulating 14-3-3η. [Abstract]2024 Jul 2;14(1):15246. PMID: 38956068 -
Fish Shellfish Immunol
Polysaccharide extract from pomelo fruitlet ameliorates diet-induced nonalcoholic fatty liver disease in hybrid grouper (Epinephelus lanceolatus♂ × Epinephelus fuscoguttatus♀). [Abstract]2021 Dec:119:114-127. PMID: 34607007 -
Heliyon
Air-ventilated normothermic machine perfusion alleviates hepatic injury from DCD rat through CYP1A2. [Abstract]2023 Aug 19;9(8):e19150. PMID: 37654459 -
BMC Cancer
PPARα ligand, AVE8134, and cyclooxygenase inhibitor therapy synergistically suppress lung cancer growth and metastasis. [Abstract]2019 Dec 2;19(1):1166. PMID: 31791289 -
PPAR Res
PPAR α Agonist WY-14643 Relieves Neuropathic Pain through SIRT1-Mediated Deacetylation of NF- κ B. [Abstract]2020 Dec 14:2020:6661642. PMID: 33414819 -
Immunol Res
TLR-2-mediated metabolic reprogramming participates in polyene phosphatidylcholine-mediated inhibition of M1 macrophage polarization. [Abstract]2020 Feb;68(1):28-38. PMID: 32248343 -
J Biochem Mol Toxicol
mTORC2 knockdown mediates lipid metabolism to alleviate hyperlipidemic pancreatitis through PPARα. [Abstract]2024 Aug;38(8):e23802. PMID: 39132808 -
Hereditas
Inhibition of ferroptosis-related NCF2 blocks the progression of lupus nephritis by activating PPARα pathway. [Abstract]2025 Oct 1;162(1):201. PMID: 41035016 -
Theriogenology
Salidroside improves bovine embryo quality by mitigating oxidative stress and regulating mitochondrial lipid metabolism. [Abstract]2025 Nov:247:117570. PMID: 40652734 -
Toxicon
A Dendrobium chrysotoxum extract erianin induce AML cells death by activating PPARɑ and downregulating PI3K/AKT signaling pathways. [Abstract]2025 Apr 23:261:108371. PMID: 40280444 -
Behav Brain Res
Ubiquinol ameliorates social disruption-induced behavioral changes via modulating inflammatory responses and PPARα activation. [Abstract]2026 Jun 25:508:116215. PMID: 41962635 -
BMC Neurosci
Hydrogen alleviated cognitive impairment and blood‒brain barrier damage in sepsis-associated encephalopathy by regulating ABC efflux transporters in a PPARα-dependent manner. [Abstract]2023 Jul 20;24(1):37. PMID: 37474902 -
Urolithiasis
Sodium hexametaphosphate mitigates calcium oxalate stone formation by modulating crystallization and maintaining PPARα signaling. [Abstract]2025 Nov 18;53(1):222. PMID: 41251724 -
Islets
Annexin A1 exacerbates islet stellate cell activation by regulating triglyceride catabolism via the PPARα/ACOX1/CYP4a pathway. [Abstract]2026 Dec 31;18(1):2633793. PMID: 41723748 -
-
-
-
-
-
-
Oxid Med Cell Longev
Cholecystokinin Octapeptide Promotes ANP Secretion through Activation of NOX4-PGC-1 α-PPAR α/PPAR γ Signaling in Isolated Beating Rat Atria. [Abstract]2022 Jun 20;2022:5905374. PMID: 35770043 -
Evid Based Complement Alternat Med
Lanzhang Granules Ameliorate Nonalcoholic Fatty Liver Disease by Regulating the PPAR α Signaling Pathway. [Abstract]2022 Jan 7:2022:1124901. PMID: 35035496 -
Oxid Med Cell Longev
PPAR α Targeting GDF11 Inhibits Vascular Endothelial Cell Senescence in an Atherosclerosis Model. [Abstract]2021 Feb 25:2021:2045259. PMID: 33728018 -
Oxid Med Cell Longev
The 5-Lipoxygenase Inhibitor Zileuton Protects Pressure Overload-Induced Cardiac Remodeling via Activating PPAR α. [Abstract]2019 Nov 3;2019:7536803. PMID: 31781348
GW6471 purchased from MedChemExpress. Usage Cited in: Oxid Med Cell Longev. 2019 Nov 3;2019:7536803. [Abstract]
Cells are treated with PE (50 μM), zileuton (100 μM), and GW6471 (10 μM) for 24 h. α-Actinin staining (n = 6) results in H9c2 cells.
GW6471 purchased from MedChemExpress. Usage Cited in: Oxid Med Cell Longev. 2019 Nov 3;2019:7536803. [Abstract]
The antihypertrophic effects of zileuton ar counteracted by GW6471 as indicated by increased PE-induced hypertrophic marker transcription, cell surface area, and oxidative stress when compared with those in the PE group and PE+ zileuton group.
Solvent & Solubility
DMSO : 83.33 mg/mL (134.47 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 15% Cremophor EL 85% Saline
Solubility: 5.56 mg/mL (8.97 mM); Suspended solution; Need ultrasonic
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Florio R, et al. Effects of dichloroacetate as single agent or in combination with GW6471 and metformin in paraganglioma cells. Sci Rep. 2018;8(1):13610. Published 2018 Sep 11. [Content Brief]
[2]. Ding L, et al. Time-dependence of cardiomyocyte differentiation disturbed by peroxisome proliferator-activated receptor alpha inhibitor GW6471 in murine embryonic stem cells in vitro. Acta Pharmacol Sin. 2007 May;28(5):634-42. [Content Brief]
[3]. Castelli V, et al. PPARα-Selective Antagonist GW6471 Inhibits Cell Growth in Breast Cancer Stem Cells Inducing Energy Imbalance and Metabolic Stress. Biomedicines. 2021;9(2):127. Published 2021 Jan 28. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6138 mL | 8.0688 mL | 16.1376 mL | 40.3441 mL |
| 5 mM | 0.3228 mL | 1.6138 mL | 3.2275 mL | 8.0688 mL | |
| 10 mM | 0.1614 mL | 0.8069 mL | 1.6138 mL | 4.0344 mL | |
| 15 mM | 0.1076 mL | 0.5379 mL | 1.0758 mL | 2.6896 mL | |
| 20 mM | 0.0807 mL | 0.4034 mL | 0.8069 mL | 2.0172 mL | |
| 25 mM | 0.0646 mL | 0.3228 mL | 0.6455 mL | 1.6138 mL | |
| 30 mM | 0.0538 mL | 0.2690 mL | 0.5379 mL | 1.3448 mL | |
| 40 mM | 0.0403 mL | 0.2017 mL | 0.4034 mL | 1.0086 mL | |
| 50 mM | 0.0323 mL | 0.1614 mL | 0.3228 mL | 0.8069 mL | |
| 60 mM | 0.0269 mL | 0.1345 mL | 0.2690 mL | 0.6724 mL | |
| 80 mM | 0.0202 mL | 0.1009 mL | 0.2017 mL | 0.5043 mL | |
| 100 mM | 0.0161 mL | 0.0807 mL | 0.1614 mL | 0.4034 mL |
GW6471 Related Classifications
HY-15372 Related Classifications
Powered by Bioz